Top

Acta Diabetologica

Published in:

01-12-2020 | Diabetic Retinopathy | Original Article

MicroRNA-148a-3p alleviates high glucose-induced diabetic retinopathy by targeting TGFB2 and FGF2

Authors: Jihong Wang, Yong Yao, Kelei Wang, Jia Li, Ting Chu, Haicui Shen

Published in: Acta Diabetologica | Issue 12/2020

Abstract

Aims

Diabetic retinopathy (DR), a common complication of type 1 or type 2 diabetes mellitus, has become the leading cause of blindness among adults in working age. The dysregulation of microRNA has been reported to be strongly related to the initiation or progression of DR. However, neither the biological role nor the molecular mechanism of miR-148a-3p has been researched in DR. This study is designed to investigate the function and mechanism of miR-148a-3p in DR.

Methods

The bioinformatics analysis (Targetscan: https://www.targetscan.org/vert_72/) and numerous experiments including real-time quantitative polymerase chain reaction, terminal deoxynucleotidyltransferase dUTP nick end labeling, CCK-8, western blot, vasculogenesis and luciferase reporter assays were used to research the function and mechanism of miR-148a-3p in DR.

Results

We constructed DR cell model by treating human retinal microvascular endothelial cells (HRECs) with different concentration gradients of high glucose (HG). Additionally, HG treatment reduced miR-148a-3p level in HRECs. In function, overexpression of miR-148a-3p caused an increase in cell viability and a decrease in cell apoptosis. Besides, miR-148a-3p overexpression led to a damage on blood–retinal barrier (BRB) and suppressed angiogenesis. In mechanism, miR-148a-3p specifically bound to 3′ untranslated region of TGFB2 and FGF2. At least, rescue assays demonstrated that the inhibitive influence of miR-148a-3p mimics on BRB injury was offset by overexpression of TGFB2 and the attenuation of angiogenesis resulting from miR-148a-3p mimics was abrogated by overexpression of FGF2

Conclusions

In a word, we discovered that miR-148a-3p alleviated HG-induced DR by targeting TGFB2 and FGF2. This novel discovery indicated miR-148a-3p as a potential target for DR diagnosis or treatment.

Hu C, Jia W (2018) Diabetes in China: epidemiology and genetic risk factors and their clinical utility in personalized medication. Diabetes 67(1):3–11. https://doi.org/10.2337/dbi17-0013CrossRefPubMed

Jenkins AJ, Joglekar MV, Hardikar AA, Keech AC, O'Neal DN, Januszewski AS (2015) Biomarkers in diabetic retinopathy. Rev Diabet Stud RDS 12(1–2):159–195. https://doi.org/10.1900/rds.2015.12.159CrossRefPubMed

Moreno A, Lozano M, Salinas P (2013) Diabetic retinopathy. Nutricion Hospitalaria 28(Suppl 2):53–56. https://doi.org/10.3305/nh.2013.28.sup2.6714CrossRefPubMed

Sosna T (2016) History of diagnosis and therapy of diabetic retinopathy. Vnitr Lek 62(11 Suppl 4):S136–S141PubMed

Pelikanova T (2016) Diabetic retinopathy: pathogenesis and therapeutic implications. Vnitrni Lek 62(7–8):620–628

Csosz E, Deak E, Kallo G, Csutak A, Tozser J (2017) Diabetic retinopathy: proteomic approaches to help the differential diagnosis and to understand the underlying molecular mechanisms. J Proteom 150:351–358. https://doi.org/10.1016/j.jprot.2016.06.034CrossRef

Chen W, Lu Q, Lu L, Guan H (2017) Increased levels of alphaB-crystallin in vitreous fluid of patients with proliferative diabetic retinopathy and correlation with vascular endothelial growth factor. Clin Exp Ophthalmol 45(4):379–384. https://doi.org/10.1111/ceo.12891CrossRefPubMed

Yu Y, Zhang J, Zhu R et al (2017) The profile of angiogenic factors in vitreous humor of the patients with proliferative diabetic retinopathy. Curr Mol Med 17(4):280–286. https://doi.org/10.2174/1566524017666171106111440CrossRefPubMed

Lu TX, Rothenberg ME (2018) MicroRNA. J Allergy Clin Immunol 141(4):1202–1207. https://doi.org/10.1016/j.jaci.2017.08.034CrossRefPubMed

10.

Mohr AM, Mott JL (2015) Overview of microRNA biology. Semin Liver Dis 35(1):3–11. https://doi.org/10.1055/s-0034-1397344CrossRefPubMedPubMedCentral

11.

Dong H, Lei J, Ding L, Wen Y, Ju H, Zhang X (2013) MicroRNA: function, detection, and bioanalysis. Chem Rev 113(8):6207–6233. https://doi.org/10.1021/cr300362fCrossRefPubMed

12.

Peng JS, Chen SY, Wu CL et al (2016) Amelioration of experimental autoimmune arthritis through targeting of synovial fibroblasts by intraarticular delivery of microRNAs 140–3p and 140–5p. Arthritis Rheumatol (Hoboken, NJ) 68(2):370–381. https://doi.org/10.1002/art.39446CrossRef

13.

Miscianinov V, Martello A, Rose L et al (2018) MicroRNA-148b targets the TGF-beta pathway to regulate angiogenesis and endothelial-to-mesenchymal transition during skin wound healing. Mol Ther J Am Soc Gene Ther 26(8):1996–2007. https://doi.org/10.1016/j.ymthe.2018.05.002CrossRef

14.

Shang F, Wang SC, Hsu CY et al (2017) MicroRNA-92a mediates endothelial dysfunction in CKD. J Am Soc Nephrol JASN 28(11):3251–3261. https://doi.org/10.1681/asn.2016111215CrossRefPubMed

15.

Zhou Y, Abraham S, Andre P et al (2015) Anti-miR-148a regulates platelet FcgammaRIIA signaling and decreases thrombosis in vivo in mice. Blood 126(26):2871–2881. https://doi.org/10.1182/blood-2015-02-631135CrossRefPubMedPubMedCentral

16.

Lacerda JZ, Ferreira LC, Lopes BC et al (2019) Therapeutic potential of melatonin in the regulation of MiR-148a-3p and angiogenic factors in breast cancer. MicroRNA (Shariqah, United Arab Emirates) 8(3):237–247. https://doi.org/10.2174/2211536608666190219095426CrossRef

17.

Liang Z, Gao KP, Wang YX et al (2018) RNA sequencing identified specific circulating miRNA biomarkers for early detection of diabetes retinopathy. Am J Physiol Endocrinol Metab 315(3):E374–E385. https://doi.org/10.1152/ajpendo.00021.2018CrossRefPubMed

18.

Katagiri M, Shoji J, Inada N, Kato S, Kitano S, Uchigata Y (2018) Evaluation of vitreous levels of advanced glycation end products and angiogenic factors as biomarkers for severity of diabetic retinopathy. Int Ophthalmol 38(2):607–615. https://doi.org/10.1007/s10792-017-0499-1CrossRefPubMed

19.

Damico FM (2007) Angiogenesis and retinal diseases. Arquivos brasileiros de oftalmologia 70(3):547–553. https://doi.org/10.1590/s0004-27492007000300030CrossRefPubMed

20.

Grant MB, Afzal A, Spoerri P, Pan H, Shaw LC, Mames RN (2004) The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 13(10):1275–1293. https://doi.org/10.1517/13543784.13.10.1275CrossRefPubMed

21.

Oltra M, Vidal-Gil L, Maisto R, Sancho-Pelluz J, Barcia JM (2019) Oxidative stress-induced angiogenesis is mediated by miR-205-5p. J Cell Mol Med. https://doi.org/10.1111/jcmm.14822CrossRefPubMedPubMedCentral

22.

Ma RCW (2018) Epidemiology of diabetes and diabetic complications in China. Diabetologia 61(6):1249–1260. https://doi.org/10.1007/s00125-018-4557-7CrossRefPubMed

23.

Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet (London, England) 376(9735):124–136. https://doi.org/10.1016/s0140-6736(09)62124-3CrossRef

24.

Ebneter A, Zinkernagel MS (2016) Novelties in diabetic retinopathy. Endocr Dev 31:84–96. https://doi.org/10.1159/000439391CrossRefPubMed

25.

Gong Q, Su G (2017) Roles of miRNAs and long noncoding RNAs in the progression of diabetic retinopathy. Biosci Rep. https://doi.org/10.1042/bsr20171157CrossRefPubMedPubMedCentral

26.

Gong Q, Xie J, Liu Y, Li Y, Su G (2017) Differentially expressed microRNAs in the development of early diabetic retinopathy. J Diabetes Res. https://doi.org/10.1155/2017/4727942CrossRefPubMedPubMedCentral

27.

Ding Y, Sun X, Shan PF (2017) MicroRNAs and cardiovascular disease in diabetes mellitus. Biomed Res Int. https://doi.org/10.1155/2017/4080364CrossRefPubMedPubMedCentral

28.

Tasena H, Faiz A, Timens W et al (2018) microRNA-mRNA regulatory networks underlying chronic mucus hypersecretion in COPD. Eur Res J. https://doi.org/10.1183/13993003.01556-2017CrossRef

29.

Gershanov S, Toledano H, Michowiz S et al (2018) MicroRNA-mRNA expression profiles associated with medulloblastoma subgroup 4. Cancer Manag Res 10:339–352. https://doi.org/10.2147/cmar.S156709CrossRefPubMedPubMedCentral

30.

Chen Q, Qiu F, Zhou K et al (2017) Pathogenic role of microRNA-21 in diabetic retinopathy through downregulation of PPARalpha. Diabetes 66(6):1671–1682. https://doi.org/10.2337/db16-1246CrossRefPubMedPubMedCentral

31.

Ye EA, Liu L, Jiang Y et al (2016) miR-15a/16 reduces retinal leukostasis through decreased pro-inflammatory signaling. J Neuroinflamm 13(1):305. https://doi.org/10.1186/s12974-016-0771-8CrossRef

32.

Mitra RN, Nichols CA, Guo J et al (2016) Nanoparticle-mediated miR200-b delivery for the treatment of diabetic retinopathy. J Control Release Off J Control Release Soc 236:31–37. https://doi.org/10.1016/j.jconrel.2016.06.020CrossRef

33.

Yuan H, Xu X, Feng X et al (2019) A novel long noncoding RNA PGC1beta-OT1 regulates adipocyte and osteoblast differentiation through antagonizing miR-148a-3p. Cell Death Differ 26(10):2029–2045. https://doi.org/10.1038/s41418-019-0296-7CrossRefPubMedPubMedCentral

34.

Qingjuan L, Xiaojuan F, Wei Z et al (2016) miR-148a-3p overexpression contributes to glomerular cell proliferation by targeting PTEN in lupus nephritis. Am J Physiol Cell Physiol 310(6):C470–C478. https://doi.org/10.1152/ajpcell.00129.2015CrossRefPubMed

35.

Ge H, Shrestha A, Liu C, Wu P, Cheng B (2018) MicroRNA 148a–3p promotes thrombospondin-4 expression and enhances angiogenesis during tendinopathy development by inhibiting Kruppel-like factor 6. Biochem Biophys Res Commun 502(2):276–282. https://doi.org/10.1016/j.bbrc.2018.05.167CrossRefPubMed

36.

Simo R, Carrasco E, Garcia-Ramirez M, Hernandez C (2006) Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2(1):71–98. https://doi.org/10.2174/157339906775473671CrossRefPubMed

37.

Qazi Y, Maddula S, Ambati BK (2009) Mediators of ocular angiogenesis. J Genet 88(4):495–515. https://doi.org/10.1007/s12041-009-0068-0CrossRefPubMedPubMedCentral

Title: MicroRNA-148a-3p alleviates high glucose-induced diabetic retinopathy by targeting TGFB2 and FGF2
Authors: Jihong Wang
Yong Yao
Kelei Wang
Jia Li
Ting Chu
Haicui Shen
Publication date: 01-12-2020
Publisher: Springer Milan
Keywords: Diabetic Retinopathy
Diabetic Retinopathy
Published in: Acta Diabetologica / Issue 12/2020
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-020-01569-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

MicroRNA-148a-3p alleviates high glucose-induced diabetic retinopathy by targeting TGFB2 and FGF2

Abstract

Aims

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Aims

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2020

Type 1 diabetes and periodontitis: prevalence and periodontal destruction—a systematic review

Long-term follow-up of diabetic macular edema treated with dexamethasone implant: a real-life study

Lessons learned from the continuous glucose monitoring metrics in pediatric patients with type 1 diabetes under COVID-19 lockdown

Lifestyle and glycemic health 5 years postpartum in obese and non-obese high diabetes risk women

Effects of thiamine and fenofibrate on high glucose and hypoxia-induced damage in cell models of the inner blood-retinal barrier

No effect of gestational diabetes or pre-gestational obesity on 6-year offspring left ventricular function—RADIEL study follow-up

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page